Issue
Alert me when new journal issues are available via or via
Masthead page IFC Full-Text PDF (33 KB)
Editorial Board page i Full-Text PDF (58 KB)
Contents pages iv-vi Full-Text PDF (49 KB)
News and Topics
Review of the bylaws changes from the Society of Urologic Oncology 2009 Jeffrey M. Holzbeierlein page 465 Full Text | Full-Text PDF (70 KB)
Review Article
Prostate-sparing cystectomy: A review of the oncologic and functional outcomes. Contraindicated in patients with bladder cancer, 13 October 2008 John P. Stein, Richard E. Hautmann, David Penson, Donald G. Skinner pages 466-472 Abstract | Full Text | Full-Text PDF (187 KB)
Original Articles
Prostate tumor alignment and continuous, real-time adaptive radiation therapy using electromagnetic fiducials: Clinical and cost-utility analyses, 14 July 2008 Martin M. Quigley, Timothy P. Mate, John E. Sylvester pages 473-482 Abstract | Full Text | Full-Text PDF (1427 KB)
Intraoperative frozen biopsy in wide surgical excision of Paget's disease of the scrotum, 17 April 2009 Ke Xu, Zujun Fang, Jie Zheng, Yong Lu, Bingkun Li, Chuanyu Sun, Qiang Ding pages 483-485 Abstract | Full Text | Full-Text PDF (109 KB)
Clinical use of serum CA-125 levels in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder, 16 June 2008 Erik J. Kouba, Aaron Lentz, Eric M. Wallen, Raj S. Pruthi pages 486-490 Abstract | Full Text | Full-Text PDF (150 KB)
Preoperative hydronephrosis as an indicator of survival after radical cystectomy, 28 July 2008 Darren M. Chapman, Kamal S. Pohar, Michael C. Gong, Robert R. Bahnson pages 491-495 Abstract | Full Text | Full-Text PDF (557 KB)
Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): A trial of the Eastern Cooperative Oncology Group, 22 July 2008 Jeffrey M. Ignatoff, Yu-Hui Chen, Richard Evan Greenberg, Julio M. Pow-Sang, Edward M. Messing, George Wilding pages 496-501 Abstract | Full Text | Full-Text PDF (164 KB)
Genetic profile identification in clinically localized prostate carcinoma, 05 June 2008 Michele Gallucci, Roberta Merola, Costantino Leonardo, Piero De Carli, Antonella Farsetti, Steno Sentinelli, Isabella Sperduti, Marcella Mottolese, Paolo Carlini, Erika Vico, Giuseppe Simone, AnnaMaria Cianciulli pages 502-508 Abstract | Full Text | Full-Text PDF (448 KB)
A single institution experience with biochemical recurrence after radical prostatectomy for tumors that on pathology are of small volume or “insignificant”, 14 July 2008 I.M. van Oort, Dieuwertje E.G. Kok, Lambertus A. Kiemeney, Christina A. Hulsbergen-van de Kaa, J. Alfred Witjes pages 509-513 Abstract | Full Text | Full-Text PDF (201 KB)
Relook TURBT in superficial bladder cancer: Its importance and its correlation with the tumor ploidy, 22 July 2008 Udai S. Dwivedi, Abhay Kumar, Suren K. Das, Sameer Trivedi, Mohan Kumar, Shyam Sunder, Pratap B. Singh pages 514-519 Abstract | Full Text | Full-Text PDF (166 KB)
Prostate carcinoma spatial distribution patterns in Chinese men investigated with systematic transperineal ultrasound guided 11-region biopsy, 14 July 2008 Weigang Yan, Hanzhong Li, Yi Zhou, Zhongming Huang, Shi Rong, Ming Xia, Zhigang Ji, Jie Chen, Yuxin Jiang pages 520-524 Abstract | Full Text | Full-Text PDF (222 KB)
PSMA expression in Schwannoma: A potential clinical mimicker of metastatic prostate carcinoma, 05 June 2008 Wenle Wang, Fabio Tavora, Rajni Sharma, Mario Eisenberger, George J. Netto pages 525-528 Abstract | Full Text | Full-Text PDF (1346 KB)
Robotic-assisted laparoscopic and radical retropubic prostatectomy generate similar positive margin rates in low and intermediate risk patients, 22 July 2008 Timo A.J. Laurila, Wei Huang, David F. Jarrard pages 529-533 Abstract | Full Text | Full-Text PDF (152 KB)
Management of Stage II testicular seminoma over a period of 40 years, 13 October 2008 Beatrice Detti, Lorenzo Livi, Silvia Scoccianti, Mauro Gacci, Alberto Lapini, Tommaso Cai, Icro Meattini, Anna Maria Mileo, Alberto Iannalfi, Alessio Bruni, Giampaolo Biti pages 534-538 Abstract | Full Text | Full-Text PDF (314 KB)
Tissue-selective RNA interference in prostate cancer cell using prostate specific membrane antigen promoter/enhancer, 22 July 2008 Weiming Zhao, Yong Xu, Deling Kong, Ranlu Liu, Zijian Zhang, Chengjun Jin, Zhihong Zhang, Youcheng Xiu pages 539-547 Abstract | Full Text | Full-Text PDF (1730 KB)
EGFR mutation in kidney carcinoma confers sensitivity to gefitinib treatment: A case report, 14 July 2008 Aglaya G. Iyevleva, Alexey V. Novik, Vladimir M. Moiseyenko, Evgeny N. Imyanitov pages 548-550 Abstract | Full Text | Full-Text PDF (496 KB)
Seminar Section Introduction
Innovations in urology from military medicine Judd W. Moul pages 551-552 Full Text | Full-Text PDF (84 KB)
Seminar Articles
Advances made in the treatment of testicular cancer in the U.S. Military: 1946 to the present Dorota J. Hawksworth, David G. McLeod, Stephen A. Brassell pages 553-557 Abstract | Full Text | Full-Text PDF (152 KB)
United States military contributions to the National Cancer Institute Jamey A. Sarvis, Ian M. Thompson pages 558-561 Abstract | Full Text | Full-Text PDF (230 KB)
The center for prostate disease research (CPDR): A multidisciplinary approach to translational research Stephen A. Brassell, Albert Dobi, Gyorgy Petrovics, Shiv Srivastava, David McLeod pages 562-569 Abstract | Full Text | Full-Text PDF (1086 KB)
Survey Section Editorial Board page 570 Full-Text PDF (37 KB)
Urologic Oncology Survey
Commentary on A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation: Figg WD, Hussain MH, Gulley JL, Arlen PM, Aragon-Ching JB, Petrylak DP, Higano CS, Steinberg SM, Chatta GS, Parnes H, Wright JJ, Sartor O, Dahut WL, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD Donald L. Trump page 571 Abstract | Full Text | Full-Text PDF (94 KB)
Commentary on Bevacizumab plus interferonα compared with interferonα monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206: Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ, Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH Donald L. Trump pages 571-572 Abstract | Full Text | Full-Text PDF (104 KB)
Commentary on Randomized phase II trial of first-line treatment with sorafenib vs. interferonα-2a in patients with metastatic renal cell carcinoma: Escudier B, Szczylik C, Hutson TE, Demkow T, Staehler M, Rolland F, Negrier S, Laferriere N, Scheuring UJ, Cella D, Shah S, Bukowski RM, Institut Gustave Roussy, Villejuif, France Donald L. Trump page 572 Abstract | Full Text | Full-Text PDF (76 KB)
Commentary on Sequential therapy with sorafenib and sunitinib in renal cell carcinoma: Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C, Department of Medicine, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN Donald L. Trump page 573 Abstract | Full Text | Full-Text PDF (71 KB)
Commentary on Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma: Thomas AA, Rini BI, Lane BR, Garcia J, Dreicer R, Klein EA, Novick AC, Campbell SC, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH Donald L. Trump page 573 Abstract | Full Text | Full-Text PDF (71 KB)
Commentary on Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: A contemporary series: Weight CJ, Garcia JA, Hansel DE, Fergany AF, Campbell SC, Gong MC, Jones JS, Klein EA, Dreicer R, Stephenson AJ, Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH Donald L. Trump page 574 Abstract | Full Text | Full-Text PDF (72 KB)
Commentary on Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer: Millikan RE, Wen S, Pagliaro LC, Brown MA, Moomey B, Do KA, Logothetis CJ, Department of Genitourinary Medical Oncology, University of Texas, M.D. Anderson Cancer Center, Houston, TX Donald L. Trump pages 574-575 Abstract | Full Text | Full-Text PDF (82 KB)
Commentary on Provider case volume and outcomes following prostate brachytherapy: Chen AB, D'Amico AV, Neville BA, Steyerberg EW, Earle CC, Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA Brent K. Hollenbeck page 575 Abstract | Full Text | Full-Text PDF (71 KB)
Commentary on Factors predicting health-related quality of life recovery in patients undergoing surgical treatment for renal tumors: Prospective evaluation using the RAND SF-36 health survey: Novara G, Secco S, Botteri M, De Marco V, Artibani W, Ficarra V, Department of Oncological and Surgical Sciences, Urologic Clinic, University of Padua, Padua, Italy Brent K. Hollenbeck pages 575-576 Abstract | Full Text | Full-Text PDF (87 KB)
Commentary on Lack of comprehension of common prostate cancer terms in an underserved population: Kilbridge KL, Fraser G, Krahn M, Nelson EM, Conaway M, Bashore R, Wolf A, Barry MJ, Gong DA, Nease RF Jr., Connors AF, Massachusetts General Hospital, General Medicine Unit, Boston, MA Brent K. Hollenbeck page 576 Abstract | Full Text | Full-Text PDF (77 KB)
Commentary on Cancer survivors and unemployment: A meta-analysis and meta-regression: de Boer AG, Taskila T, Ojajarvi A, van Dijk FJ, Verbeek JH, Coronel Institute of Occupational Health, Academic Medical Center, Amsterdam, The Netherlands Brent K. Hollenbeck page 577 Abstract | Full Text | Full-Text PDF (72 KB)
Commentary on Prostate cancer severity among low income, uninsured men: Miller DC, Litwin MS, Bergman J, Stepanian S, Connor SE, Kwan L, Aronson WJ, Department of Urology, University of California, Los Angeles, CA Brent K. Hollenbeck pages 577-578 Abstract | Full Text | Full-Text PDF (82 KB)
Commentary on Telomere length in peripheral blood predicts survival in clear cell renal cell carcinoma: Svenson U, Ljungberg B, Roos G, Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden Joel W. Slaton page 578 Abstract | Full Text | Full-Text PDF (72 KB)
Commentary on Urine metabolomics analysis for kidney cancer detection and biomarker discovery: Kim K, Aronov P, Zakharkin SO, Anderson D, Perroud B, Thompson IM, Weiss RH, Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, CA Joel W. Slaton pages 578-579 Abstract | Full Text | Full-Text PDF (82 KB)
Commentary on MicroRNA profiling of human kidney cancer subtypes: Petillo D, Kort EJ, Anema J, Furge KA, Yang XJ, Teh BT, Laboratory of Cancer Genetics, Van Andel Research Institute, Grand Rapids, MI Joel W. Slaton pages 579-580 Abstract | Full Text | Full-Text PDF (82 KB)
Commentary on Specific reduction of Fas-associated protein with death domain (FADD) in clear cell renal cell carcinoma: Xu H, He L, Feng X, Kapoor A, Tang D, Department of Nephrology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China Joel W. Slaton page 580 Abstract | Full Text | Full-Text PDF (72 KB)
Commentary on Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer: Yuen JS, Akkaya E, Wang Y, Takiguchi M, Peak S, Sullivan M, Protheroe AS, Macaulay VM, Weatherall Institute of Molecular Medicine, University of Oxford, Headley Way, Headington, Oxford, United Kingdom Joel W. Slaton pages 580-581 Abstract | Full Text | Full-Text PDF (83 KB)
Commentary on Antitumor effects of an imidazoquinoline in renal cell carcinoma: Schwartz MJ, Liu H, Hwang DH, Kawamoto H, Scherr DS, Department of Urology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY Joel W. Slaton page 581 Abstract | Full Text | Full-Text PDF (71 KB)
Information for Authors page IBC Full-Text PDF (36 KB)
Copyright © 2010 Elsevier, Inc. All rights reserved | Privacy Policy | Terms & Conditions | Feedback | About Us | Help | Contact Us | The content on this site is intended for health professionals.
